23andmeThe special committee of the independent directors on Monday, Anne Wojcicki's proposal to take over the distributed gen testing company privately.

Wojcicki submitted a proposal to the committee on Sunday during which he was in a position to purchase all of the outstanding shares of the corporate for 41 cents each A submission With the US Securities and Exchange Commission.

The stock fell by 33% to $ 1.47 on Monday, which declined to a decline of greater than 99% in comparison with its climax in 2021.

Wojcicki and New Mountain Capital submitted an earlier offer in February to take over the corporate privately for $ 2.53 per share. Days later New Mountain told Wojcicki that it was not concerned about participating in a possible acquisition and would hire discussions, the submission said.

23Andmes Special Committee said that Wojcicki's proposal was a decrease of 84% in comparison with the previous offer and is set not to maneuver forward, in order that it was impossible to advance, so a publication on Monday.

“In consultation with his financial and legal advisors, the special committee has checked Ms. Wojcicki's proposal and unanimously decided to reject the proposal,” said the administrators.

A representative of 23Andme rejected an announcement.

After a turbulent 2024, 23andme announced plans to explore in January Strategic alternativesincluding a sale of the corporate or its assets, a restructuring or an organization combination.

Wojcicki previously submitted a proposal to take over the corporate privately in July for 40 cents per share, but it surely was rejected Due to the special committee, partly since the members specified, there was no defined financing and at the moment didn’t provide a premium for the closing price.

REGARD: The increase and fall of 23andme

23andme According to a Friday submission With the US Securities and Exchange Commission.

Wojcicki and New Mountain have offered to amass all outstanding money shares of 23 and outstanding shares of $ 2.53 per share or an equity value of approx. $ 74.7 million. The company's share closed on Friday at $ 2.42 with a market capitalization of around 65 million US dollars.

The offer takes place after a turbulent 12 months for 23Andme, with the share losing greater than 80% of its value in 2024. In January the corporate announced plans for investigation Strategic alternativesincluding a sale of the corporate or its assets, a restructuring or an organization combination.

23Andme has a special committee for independent directors to judge potential paths forward. In October, the corporate appointed three latest independent directors to his Board of Directors in spite of everything seven former directors had resigned abruptly within the previous month. The special committee has to approve Wojcicki and the New Mountain's proposal.

“We believe that our proposal offers the public shareholders of the company convincing value and immediate liquidity”, wrote Wojcicki and Matthew Holt, managing director and president of personal equity at New Mountain, in a letter to the special committee on Thursday.

Wojcicki previously submitted a proposal to take over the corporate privately in July for 40 cents per share, nevertheless it was rejected Due to the special committee, partly since the members specified, there was no defined financing and at the moment didn’t provide a premium for the closing price.

Wojcicki and New Mountain are able to enable secure debt financing to finance 23Ande activities by closing the transaction, the submission said. New Mountain relies in New York and, in line with him, has $ 55 billion in assets website.

23Andme refused to comment.

REGARD: The increase and fall of 23andme

Competed genetic firm 23andme said on Tuesday that it began to explore Strategic alternatives For the second time, which could include a sale of the corporate or its assets, restructuring or an organization combination.

The share, which lost 82% of its value last yr, fell 10% in prolonged trade and was stopped briefly.

The announcement collapsed with the publication of 23Andme Results within the third quarter. Sales in the corporate's consumer service business decreased from $ 42.9 million within the previous yr by 8% to $ 39.6 million.

The company said that it will “need additional liquidity” to finance its business and it desires to get capital.

“Management has found that there is considerable doubts about the company's ability to continue as a matter of concern,” said 23andme on Tuesday within the profit publication.

CEO Anne Wojcicki tried to maintain the corporate afloat. 23Andme is now price lower than 100 million US dollars, which is a top value of $ 6 billion.

In March, the independent directors of 23Andme founded a special committee to guage the corporate's potential paths forward. Wojcicki submitted a proposal to take over the corporate privately in July, but it surely was rejected Because it had no fixed financing and at the moment didn’t offer a premium for the course of the ultimate act. Committee said.

The independent directors resigned from the 23Andme board every two months later, citing disagreements with Wojcicki concerning the “strategic orientation of the company”. Wojcicki has now appointed three recent independent directors to his board, and 23Andme also said that it should shorten 40% of its workforce and to modify off the therapeutic business as a part of a restructuring plan.

On Tuesday, 23Andme said that the special committee would again monitor the seek for strategic alternatives, in response to A release. The committee chosen Moelis & Company as a financial advisor and Goodwin Procter as a legal advisor.

There is not any guarantee that a deal will happen, the committee said. Wojcicki has repeatedly expressed her want to take the corporate privately, but it surely isn’t clear whether she is going to submit one other proposal.

23Andme refused to comment.

REGARD: The increase and fall of 23andme

23andMe reported a decline in revenue in its most up-to-date quarter on Tuesday, a day after the corporate said it will cut 40% of its workforce and shut its therapeutics business amid a crisis Corporate restructuring plan.

The troubled genetics company reported revenue of $44.1 million in its fiscal second quarter, compared with $50 million in the identical period last 12 months. 23andMe's net loss narrowed to $59.1 million, or $2.32 per share, in comparison with $75.27 million, or $3.17 per share, a 12 months ago.

23andMe said Monday that it will cut greater than 200 jobs, halt all of its therapeutic programs and terminate its ongoing clinical trials “as quickly as possible.” It is exploring strategic options akin to asset sales and licensing agreements to “maximize the value” of the therapeutic programs, the press release said.

“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer and research partnerships businesses,” Anne Wojcicki, CEO of 23andMe, said in Monday’s press release. “I would like to thank our team for their hard work and commitment to our mission. We are fully committed to supporting employees affected by this transition.”

The company said Tuesday it could look to boost additional capital.

Shares of 23andMe closed up 2% on Tuesday. They have slumped about 75% this 12 months after losing greater than half their value in 2023, pushing the corporate's market cap to $100 million.

Wojcicki, co-founder of 23andMe in 2006, has worked to maintain the corporate afloat after it was at risk of being delisted from Nasdaq. Shares hovered below $1 until 23andMe announced a 1-for-20 ratio reverse stock split in October.

In September, all seven of the corporate's independent directors suddenly resigned from the board, writing in a letter that they disagreed with Wojcicki over the “strategic direction of the company.” At the tip of October, three recent independent directors were appointed to the board.

“We have met our obligations as a publicly traded company and regained compliance with NASDAQ listing standards by reconstituting our board of directors and executing a reverse stock split,” Wojcicki said during 23andMe's conference call on Tuesday.

Wojcicki has repeatedly said she intends to maintain 23andMe private, but didn’t comment on the plans Tuesday. In one Submission in September She said she wouldn’t consider third-party takeover proposals and said the “best path forward” for her was to take the corporate private.

23andMe declined to comment.

REGARD: The rise and fall of 23andMe

All seven independent directors of 23andMe resigned from the corporate's board on Tuesday. CEO Anne Wojcicki said in a memo to employees that she was “surprised and disappointed” by the move.

Wojcicki, who co-founded 23andMe in 2006, said she stays committed to taking the corporate private.

The genetic testing company went public in 2021 via a special purpose acquisition company (SPAC), and its share price has been largely in free fall since then, falling greater than 95% from its peak. Directors formed a special committee in late March to explore potential ways forward.

Wojcicki submitted a proposal to denationalise the corporate in July, but rejected rejected by the Special Committee, also since it didn’t grant a premium on the then closing price of 40 cents per share.

In a letter In response to Wojcicki on Tuesday, the administrators said they’d not yet seen a “fully funded, carefully crafted and actionable proposal that is in the best interests of unaffiliated shareholders.” The directors said they disagreed with Wojcicki on the “strategic direction of the company” and had due to this fact decided to resign effective immediately.

“Given that we have not seen any significant progress over the past five months, we believe no such proposal is on the horizon,” they wrote. “The Special Committee is therefore not prepared to consider any further extensions and the Board concurs with the Special Committee's decision.”

Wojcicki wrote in the worker memo, seen by CNBC, that she still sees taking 23andMe private because the “best opportunity for long-term success.” The company will begin searching for brand new independent board members, she added.

Far from its former valuation of $3.5 billion, 23andMe now has a market capitalization of lower than $200 million. Shares closed at 34 cents on Tuesday.

Here is Wojcicki’s full memo:

REGARD: 23andMe CEO requests company to be privatized

Anne Wojcicki, CEO of 23andMehas filed to take the genetic testing company private as its share price stays below $1.

Wojcicki said she was willing to buy all of 23andMe’s outstanding common stock in money for 40 cents per share, in response to a Wednesday registration on the US Securities and Exchange Commission (SEC). In April, it expressed interest in acquiring the corporate, but said on the time that it was “not prepared to support an alternative transaction.”

The proposed price of 40 cents per share represents an 11% premium to 23andMe's closing price in April. Wojcicki's intention is to finish the transaction “as quickly as possible,” the filing said.

23andMe shares closed at 40 cents on Wednesday.

The former billionaire co-founded the corporate in 2006 and his at-home DNA testing kits, designed to provide customers insight into their family history and genetic profile, made it immediately mainstream. 23andMe went public in 2021 through a merger with a special purpose acquisition company that valued the corporate at around $3.5 billion.

However, the corporate has struggled to generate regular, recurring revenue because customers only need to make use of the DNA product once to get their results. The company's shares have fallen greater than 95% since its debut.

“Our experience with the short-term focus of the public markets has led me to believe that the Company is best equipped to execute this mission as a private company, allowing us to avoid certain costs and distractions associated with being a publicly traded company,” Wojcicki wrote within the proposal.

In November, the corporate received a Defect letter from the Nasdaq Listing Qualifications Department, which said the corporate had 180 days to get its stock price back above $1. The company's board of directors formed a “special committee” in late March to review options that would boost the stock price.

The special committee must approve or reject Wojcicki's proposal to denationalise the corporate, in response to Wednesday's documents.

23andMe declined to comment.

Anne Wojcicki, the CEO of 23andMeis considering a proposal to delist the genetic testing company after its share price plunged greater than 95% from its 2021 highs.

A filing late Wednesday Speaking to the Securities and Exchange Commission, Wojcicki said he’s working with advisers and plans to seek advice from potential funding sources and partners. It “wishes to maintain control of the company” and is “unwilling to support an alternative transaction,” the filing said.

The former billionaire co-founded 23andMe in 2006, and the corporate skyrocketed in popularity due to its at-home DNA testing kits that give customers insight into their family history and genetic profile. 23andMe went public in 2021 through a merger with a special purpose acquisition company that valued the corporate at around $3.5 billion.

But 23andMe struggled to generate consistent recurring revenue because customers only needed to take the DNA test once to receive their results. The stock closed Thursday at around 51 cents per share.

In November, 23andMe received one Notice of defects from the Nasdaq Listing Qualifications Department, which said the corporate has 180 days to get its share price back above $1. The company's board formed a “special committee” in late March to assist examine options that might boost the stock.

A Press release said Thursday that the committee had been made aware of Wojcicki's interest in acquiring all of 23andMe's outstanding shares. Wojcicki owns shares representing greater than 20% of the shares outstanding, which represents about 49% of the voting rights, the discharge said.

“The Special Committee will carefully consider Ms. Wojcicki's proposal when it is made available and evaluate it in light of other available strategic alternatives, including continuing to operate as a publicly traded company,” the committee said in the discharge. “The Special Committee is committed to acting in the best interests of 23andMe and its shareholders.”

The committee hired Wells Fargo as its financial adviser and said there was “no guarantee” that Wojcicki's offer would produce the proposed consequence.

23andMe declined to comment beyond publication.